Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Kanghong's VEGF Fusion Drug Granted Three US SPAs for Retinal Diseases

publication date: Feb 3, 2021

Chengdu Kanghong Pharma announced conbercept was granted Special Protocol Assessments in the US for three new retinal indications. Conbercept is an anti-VEGF fusion protein, approved and marketed in China as Lumitin^® to treat retinal diseases. The additional indications are DME (Diabetic Macular Edema) and RVO (Central Retinal Vein Occlusion and Branch Retinal Vein Occlusion), which can cause blurred vision and sudden vision loss. The SPA may also lead to a wider treatment range for conbercept in age-related macular degeneration and blindness. More details....

Stock Symbol: (SHZ: 002773)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.